semaj83/ctmatch_classification huggingface dataset:
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Heart Failure Symptomatic heart failure and indication for cardiac resynchronization therapy (CRT), Hemodynamic stability with documented intolerance to beta-blocker therapy or treatment with beta-blocking agents at sub-optimal dosages (<25% of optimal dosage)  chronic atrial fibrillation; indications for permanent antibradycardia pacing; mechanical tricuspid valve; Severe aortic stenosis or other primary valve disease causing cardiomyopathy
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Lung Cancer Patients must be enrolled in the trial: "A Phase I/II Trial of Neoadjuvant Paclitaxel, Carboplatin and OSI-774 (Tarceva) with Concurrent Accelerated Hyperfractionation Radiation Followed by Maintenance Therapy with OSI-774 for Stage III Non-Small Cell Lung Cancer," Principal Investigator: T. Mekhail, M.D Patient must be in maintenance therapy phase of the study and have received erlotinib for ≥ 1 week No known CNS primary or metastatic cancer at any time prior to time of enrollment No MRI evidence of pathological enhancement at the time of study entry Patients must use adequate birth control measures while in the study No significant side effects to erlotinib that require dose reduction or interruption None of the following medical issues which could make a lumbar puncture unsafe Platelets < 100,000/mm³ INR > 1.1 Known bleeding dyscrasia
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 30.0-999.0,  Congestive Heart Failure (CHF) Physician diagnosed CHF Member of Kaiser Permanente Georgia
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Congestive Heart Failure Patients will be recruited from the cardiology clinic at Hennepin County Medical Center. Patients are eligible for the study if they are Older than 18 Not pregnant Have heart failure with worsening hypervolemia despite oral diuretics Have at least two of the following signs or symptoms of hypervolemia: JVD, edema >1+, rales pulmonary edema on chest x-ray, orthopnea or PND Not more than 10 kg above their usual baseline weight Have, in the opinion of the treating physician, a need for a minimum of 2 liters of volume removal  Systolic blood pressure < 90 mmHg Serum creatinine > 3.0 mg/dL Hematocrit >45 % Uncontrolled arrhythmias Need for hospitalization Require renal replacement therapy Contraindication to anticoagulation with heparin Poor venous access
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Heart Failure Hospitalized for episode of worsening heart failure as primary cause of admission or significant heart failure symptoms that develop during the hospitalization when the initial reason for admission was not heart failure Systolic dysfunction (LVEF < 40%) or heart failure symptoms in the setting of preserved systolic function (diastolic dysfunction)  This study has no
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Congestive Heart Failure Clinical diagnosis of heart failure based on a slight modification of the Framingham as previously described within 6 months before the entry Current status of heart failure is NYHA II or III Currently, loop diuretic(s) is (are) administered No change in baseline therapy and symptoms of heart failure within a month  Current symptomatic hypotension Hypertension that has not been controlled to the satisfaction of the investigator Hemodynamically significant (in the investigators opinion) LV outflow tract obstruction (due to either aortic stenosis or ventricular hypertrophy) Acute coronary syndrome Primary pulmonary hypertension or pulmonary hypertension not due to LV dysfunction Serious cerebrovascular disease Acute myocardial infarction within the last 3 months Patients who require intravenous inotropes Cerebrovascular accident within the last 3 months Percutaneous coronary intervention or open heart surgery within the last 3 months
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Hypertension African-American males and females current diagnosis of type 2 diabetes documented by medical history mean sitting diastolic blood pressure of ≥ 90 and ≤ 110 mm Hg HbA1C ≤ 9.5%  having unilateral or bilateral renal artery stenosis having clinically significant cardiac dysrhythmias having a significant history of coronary artery disease within the past 6 months having a history or diagnosis of congestive heart failure (CHF) having any clinically relevant cardiac valvular disease
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Heart Failure, Congestive primary hospitalization with heart failure and LVEF < 40% patient informed consent has been obtained absence of pulmonary congestion age > 18 years  End-stage renal or hepatic disease Acute myocardial infarction as primary diagnosis during index hospitalization Life-expectancy < 6-months Contraindication to beta blocker use Current beta-blocker therapy Planned bypass or valve surgery during index hospitalization
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 45.0-999.0,  Congestive Heart Failure Age over 45 years old CHF class II or III with LVEF<40% Hospitalized at least once for CHF deterioration over previous 12 month period Able and willing to cooperate with this trial for at least a 3 month period Home close to participating center  Recent (within 3 month) admission to ICU or CC-ICU due to severe CHF episode requiring artificial ventilation Asthma or COPD
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Prostate Cancer Histologically confirmed adenocarcinoma of the prostate meeting any of the following for high-risk disease Clinical stage II or III (T2b, T2c, or T3 with any grade or prostate-specific antigen [PSA]) Gleason score 7 (4+3 only) or ≥ 8 (any stage or PSA) Serum PSA ≥ 10 ng/dL (any grade or stage) Any stage, PSA, or Gleason score with ≥ 35% chance of biochemical failure at 5 years based on Kattan's nomogram No clinical evidence of CNS metastases No metastatic disease as demonstrated by radiological exam (CT scan, MRI, bone scan, x-ray) within 8 weeks of study entry Appropriate medical candidate for radical prostatectomy ECOG performance status 0-1 Creatinine ≤ 2.0 mg/dL
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Congestive Heart Failure NYHA III-IV QRS > 120 msec On medical therapy, but beta blocker dose not @ target (carvedilol 25 bid, metoprolol succinate 200 qd)  QRS < 120 msec On target beta blocker dose
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Heart Diseases Advanced HF (Stage D or advanced Stage C HF) with symptoms of dyspnea at rest or with minimal exertion systolic dysfunction or preserved systolic function ("diastolic heart failure") Outpatient care setting (office, clinic or home hospice) Patient already receiving optimal medical therapy per ACC/AHA guidelines (ACEI or ARB + β-blocker +aldosterone antagonist) for at least 1 month or explanation of intolerance of specific medication. We will those not on optimized medications with no notation of intolerance; however, we will keep a tally to quantify patients who are considered "advanced Heart Failure" but are not on recommended medications Can be awaiting LVAD, transplantation or other procedure Age > 18 years and able to sign informed consent to participate  Cognitive or other impairment which prevents accurate assessment of symptoms or ability to provide informed consent Heart failure due to recent onset of acute viral myocarditis, peripartum myocarditis Patient on hemodialysis or receiving mechanical ventilation Patients receiving investigational agents or devices Patients who have received heart transplant or a destination Left Ventricular Assist Device
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Obstructive Sleep Apnea Syndrome Obstructive sleep apnea syndrome based on symptoms and a sleep study  Sleep disorders other than obstructive sleep apnea syndrome Other than mild, stable cardiovascular disease Other than mild lung disease Chronic rhinitis, previous uvulopalatopharyngoplasty Treatment with drugs that affect respiratory center drive Internal, neurologic or psychiatric disease that interferes with sleep quality Previous intolerance to moderate or low altitude < 2600m
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Mellitus Females of childbearing potential must be using appropriate birth during the entire duration of the study or must be surgically sterile Subjects with a clear diagnosis of type 2 diabetes mellitus using diagnostic of the American Diabetes Association who have been taking a sulfonylurea and/or insulin for at least 30 days prior to Visit 1 or who have been withdrawn from metformin therapy, during the 30 days prior to Visit 1, due to congestive heart failure Subjects with a clinical diagnosis of congestive heart failure, New York Heart Association Class II or early Class III. Subjects should not previously have been in Class IV heart failure Diagnosis of left ventricular congestive heart failure as evidenced by a left ventricular ejection fraction less than 40% at screening based on an echocardiogram Subjects who have demonstrated the need for oral hypoglycemic agents and have participated in dietary counseling Glycosylated hemoglobin greater than 7.0% at screening Subjects on optimal therapy for congestive heart failure. Medication doses should be stable for at least two weeks prior to randomization  Naïve to antidiabetic therapy Within the past three months were treated with rosiglitazone, pioglitazone HCl, or troglitazone or those previously treated with rosiglitazone, pioglitazone HCl, or troglitazone but discontinued from therapy due to lack of efficacy or clinical or laboratory signs of intolerance Type 1 (insulin-dependent) diabetes mellitus or a history of ketoacidosis Has taken any other investigational drug during the 30 days prior to Visit 1 or who will receive such a drug during the timeframe of this study History of chronic alcoholism or drug abuse during the six months prior to the study Has had any of the following within three months prior to Visit 1: myocardial infarction, coronary angioplasty or bypass graft, unstable angina pectoris, transient ischemic attacks, or documented cerebrovascular accident that in the investigator's opinion would warrant from the study Abdominal, thoracic, or vascular surgery during the three months prior to Visit 1 that in the investigator's opinion would warrant from the study Subjects with a planned surgical or catheterization intervention within the six months following Visit 1 Subjects awaiting cardiac transplantation Intercurrent illness severe enough to require hospitalization during the three weeks prior to Visit 1
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Heart Failure HF by Framingham At least one admission to hospital for HF within the last 180 days New York Heart Association Class II thru IV Echocardiographic criteria:At least moderate diastolic dysfunction, Ejection fraction >45%  Creatinine clearance <40 mls/min/1.73m2 Potassium >5.0 mmol/L Recent acute coronary syndrome in the prior 4 weeks Planned revascularization, defibrillator or pacemaker in next 4 months Known previous intolerance to aldosterone antagonist
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Heart Failure, Congestive Received or is eligible to receive a principal hospital discharge diagnosis of HF or decompensated HF is present as determined clinically by the patient care team  Heart Failure is present as a co-morbid condition, but is not a principal focus of diagnosis or treatment during this hospitalization episode
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Congestive Heart Failure age18 or older primary diagnosis of CHF in the Emergency Department admission to the hospital or transfer to the Observation Unit  minors, prisoners,pregnant women,unable to provide consent unstable angina or acute myocardial infarction in the ED dialysis dependent patients use of nesiritide as a therapy in the ED
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Rheumatoid Arthritis Interstitial Pneumonia Diagnosis of RA according to the revised 1987 American Rheumatism Association Absence of clinical features suggesting infection, neoplasm, sarcoidosis, interstitial lung disease other than UIP or NSIP, other collagen vascular disease, or exposure to known fibrogenic drugs or environmental factors Diagnosis of progressive interstitial pneumonia of UIP or NSIP subtype, based on the following Clinical symptoms consistent with interstitial lung disease with onset between 3 months and 36 months prior to screening Worsening as demonstrated by any one of the following within the past year > 10% decrease in Forced Vital Capacity (FVC) increasing infiltrates on chest X-ray or High Resolution Computed Tomography (HRCT), or worsening dyspnea at rest or on exertion Diagnosis of UIP or NSIP by either of the following Open or video-assisted thoracic surgery (VATS) lung biopsy showing definite or probable UIP or NSIP HRCT scan showing definite or probable UIP or NSIP AND abnormal pulmonary function tests (reduced FVC or decreased diffusing capacity of carbon monoxide (DLco) or impaired gas exchange at rest or with exercise) AND insidious onset of otherwise unexplained dyspnea or exertion and bibasilar, inspiratory crackles on auscultation  History of clinically significant environmental or drug exposure known to cause pulmonary fibrosis Forced expiratory volume in one second (FEV1) FEV1/FVC ratio < 0.6 at screening (pre or post-bronchodilator) Residual volume > 120% predicted at Screening Evidence of active infection Any pulmonary condition other than UIP/NSIP, which, in the opinion of the site principal investigator, is likely to result in the death of the patient within the next year History of unstable or deteriorating cardiac or neurologic disease Pregnancy or lactation Treatment with cyclophosphamide, cyclosporine, interferon gamma or beta, anti-tumor necrosis factor therapy, anti-interleukin 1 (IL1) therapy or with endothelin receptor blockers within the last 8 weeks; experimental therapy for rheumatoid arthritis Creatinine > 1.5 X upper limit of normal range (ULN) at Screening
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Atrial Fibrillation Congestive Heart Failure Left ventricular ejection fraction </=35% as measured by nuclear imaging, echocardiography, or cardiac angiography within 6 months preceding enrollment. If the patient has had a myocardial infarction or heart surgery during this period, the ejection fraction must be remeasured Symptomatic CHF (NYHA class II-IV) at some time during the 6 months before randomization, despite therapy with an ACE inhibitor (however, patients who do not tolerate an ACE inhibitor are eligible). Asymptomatic patients (NYHA class I) with either a prior hospitalization for CHF during the 6 months before randomization or with a left ventricular ejection fraction of </=25% are also eligible History of significant AF, defined as either one episode lasting >/=6 hours (duration of AF will be determined by history), within the past 6 months with electrocardiographic confirmation; or an episode lasting >/=10 minutes (by history) within the past 6 months with electrocardiographic confirmation in a patient with a prior electrical cardioversion for AF In the opinion of the clinical investigator, the patient must be eligible for long-term treatment with either treatment strategy of AF  AF is known to be present and uninterrupted for more than 12 months prior to randomization. However, if such a patient is cardioverted and maintained in sinus rhythm for >/=24 hours, he or she becomes eligible Reversible cause of AF such as acute pericarditis, pulmonary embolism, hyperthyroidism, alcohol intoxication AF occurring and not persisting beyond 10 days of surgery or myocardial infarction Reversible cause of CHF such as severe aortic or mitral stenosis and tachycardia-induced cardiomyopathy Decompensated CHF within 48 hours of randomization Antiarrhythmic drugs other than calcium channel blockers, beta-blockers or digoxin required for other arrhythmias or other indications More than 7 days of amiodarone therapy within the last month prior to randomization Second or third degree AV block, sinus pause >3 seconds, resting heart rate <50 bpm without a permanent pacemaker History of drug-induced Torsades de Pointes or congenital long QT syndrome Prior AV nodal ablation or Maze surgery